OncLive TV

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer. 

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

Carey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer.

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

James P. Allison, PhD, discusses his experience with the urgency of drug development in oncology. 

Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer. 

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.

Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to be a good mentor for fellows in oncology.

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss the importance of having a mentor during fellowship.

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer. 

James P. Allison, PhD, discusses the development of ipilimumab.

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Rodolfo Bordoni, MD, discusses the utility of ​atezolizumab in the adjuvant setting in non–small cell lung cancer.